AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02576782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perineural Dexamethasone and bupivacaine
Study NCT02576782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Dexamethasone plus perineural bupivacaine
Study NCT02576782 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: intravenous saline plus perineural bupivacaine
Study NCT00543400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M118
Description: intravenous (IV) infusion
Study NCT00543400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated Heparin
Description: IV infusion
Study NCT00748124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PleuraSeal Sealant System
Description: Lung Sealant Device + standard tissue closing techniques (sutures/staples)
Study NCT00748124 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Tissue Closure Techniques
Description: Standard tissue closure techniques (sutures/ staples) alone
Study NCT00748124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Tissue Closure Techniques
Description: Standard tissue closure techniques (sutures/ staples) alone
Study NCT01584492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone+formoterol 50/6 (1 inhalation)
Description: CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
Study NCT01584492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535 50/6 (2 inhalations)
Description: CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
Study NCT01584492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535 50/6 (4 inhalations)
Description: CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
Study NCT01584492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol + Beclomethasone dipropionate
Description: * Formoterol HFA pMDI 6 µg / actuation~* Extrafine BDP HFA pMDI 50 µg/actuation
Study NCT01584492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (6 inhalations)
Description: Matched placebo via pMDI
Study NCT02342665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY80-6946)
Description: Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).
Study NCT04192513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: J. lividum
Description: Investigational Product
Study NCT03384953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Hypnosis - Group Treatment
Description: group treatment
Study NCT03384953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Hypnosis - Individual Treatment
Description: individual treatment
Study NCT01406145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0777
Description: oral tablet
Study NCT02618720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ornidazole
Study NCT02618720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02922790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard health information
Description: Subjects will review standard health information
Study NCT02922790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard health information plus info. on DNA damage
Description: Subjects will review standard health information and information on DNA damage
Study NCT02922790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage
Description: Subjects will review standard health information and information on DNA damage, as well as review pictures of their cells' DNA damage
Study NCT01855581 — intervention group
Intervention type: DRUG
Intervention: pediatric sedation (propofol, ketamine, etc)
Description: Presedation assessment was performed by hospitalists and pediatric sedation was performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events were collected retrospectively.
Study NCT02211534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Electromagnetic Field Device (Provant)
Description: The PEMF device delivers non-thermal, non-ionizing pulsed electromagnetic energy to the target tissue, using 27.12 megahertz pulses lasting 42 microseconds and delivered 1000 times per second. The system generates an electromagnetic field that is continuously monitored and regulated to ensure consistent dosing. The therapeutic electromagnetic field is delivered by means of an applicator pad that is placed against the treatment site. The active and sham devices will be identical in appearance and all other physical characteristics in order to maintain the masking of the treatment.
Study NCT01406145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study NCT02211534 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Pulsed Electromagnetic Field Device
Description: The Sham device will be identical in appearance, physical characteristics and operation to the Active device.
Study NCT03786796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is a crystalline solid, is non-chiral and shows pH-independent solubility of approximately 0.1 mg/mL across the physiological range. Olaparib is presented for oral administration as a green, film-coated tablet containing 25 mg, 100 mg or 150 mg of drug substance. The 100 mg strength is also available as a yellow, film-coated tablet. The 25 mg, 100 mg and 150 mg strengths of olaparib tablets are composed of the same constituents. The tablet cores comprise: olaparib, copovidone, colloidal silicon dioxide, mannitol and sodium stearyl fumarate. The composition of the green tablet film coating is: hydroxypropyl methylcellulose (hypromellose), macrogol 400 (polyethylene glycol 400), titanium dioxide, iron oxide yellow and iron oxide black. The yellow tablet film coating only differs from the green film coating with the omission of iron oxide black.
Study NCT03377790 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: VP-102 - Cantharidin, Topical Film Forming Solution
Description: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
Study NCT03377790 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo -Topical Film Forming Solution without VP-102
Description: Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
Study NCT01515904 — intervention group
Intervention type: BEHAVIORAL
Intervention: STOMP Clinic
Description: A new interdisciplinary clinic (STOMP) was created to provide care for children and adolescents with severe 'complex' obesity. As part of the program, a subset of adolescents undergo bariatric surgery. The core elements include an interdisciplinary team, frequent visits, individualized care plans for medically-complex adolescents) and building on other aspects, such as increased psychosocial intervention; involvement of a key worker (nurse practitioner) to support families; provision of continuity of care with other health providers in all settings, community services and schools; a more diverse patient population; and group support sessions.
Study NCT02770508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darunavir/ritonavir
Study NCT02770508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir
Study NCT02770508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Study NCT02770508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine-tenofovir(FTC/TDF)
Study NCT01216891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-element, team-oriented treatment
Description: Participants will receive treatment and services based on their needs coordinated by a small team that is led by a clinical coordinator. Services that are available to the participants include social skills training, medication treatment to address symptoms, education and employment advising, and substance use treatment.
Study NCT03717662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine gum or nicotine patch
Description: The project will provide intensive counseling at the Centre for Health Promotion (CHP) of HKU Department of Nursing Studies, female smokers who require more intensive counseling or advice on nicotine replacement therapy, upon referral from the women's organizations and trained women counselors. The smokers will receive face-to-face (or telephone) counseling and a 1 week supply of Nicotine replacement therapy (NRT) (4 mg nicotine gum or 10 mg/ 15 mg nicotine patch) from the nurse counselor, and follow up calls at 1 week, 1-, 3-, 6-, 36- and 72-month post-intervention.
Study NCT00597714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-myeloablative Stem Cell Transplantation
Description: The preparative regimen is 4 days of daily fludarabine at 40 mg/m2/d infused over 30 minutes; melphalan 140 mg/m2/d for 1 day administered over 15 minutes; 4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours. Group B's prep regimen will begin on day -5 or day -4 and busulfan 130mg/m2/d for 2 days over 3 hours. The peripheral blood stem cells (PBSCs) will be infused over 2-4 days. Patient evaluations will occur 2 times per week by physical exam for toxicity through day 45.
Study NCT00902941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilect 1mg
Description: 1 mg daily orally for 120 days
Study NCT00902941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mg daily orally for 120 days
Study NCT03375580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TLC
Description: transform life custom (TLC)
Study NCT03375580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TLC
Description: transform life custom (TLC)
Study NCT03375580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: TLC
Description: transform life custom (TLC)
Study NCT03375580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 0.5g metformin group，PO tid
Study NCT03375580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Zhenzhu Tiaozhi capsule
Description: Compound Zhenzhu Tiaozhi capsules consist of eight Chinese herbal medications, such as Ligustrum lucidum, Atractylodes macrocephala, Radix Salviae Miltiorrhizae, pseudo-ginseng, Astragalus membranaceus.
Study NCT03375580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 20mg simvastatin, PO qn
Study NCT02486549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supraclavicular Block
Description: Under ultrasound guidance an insulated needle is advanced with in- plane technique into the brachial plexus sheath and 20ml 0.25% bupivacaine will be administered
Study NCT02486549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Block
Description: Under ultrasound guidance an insulated needle will be placed through the middle scalene muscle,into the interscalene groove with in-plane technique and 20ml 0.25%bupivacaine will be administered into the brachial plexus
Study NCT02486549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20ml 0.25% bupivacaine will be injected for brachial plexus block
Study NCT02486549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 20ml 0.25% bupivacaine will be injected for brachial plexus block
Study NCT02486549 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: The Ultrasound will be used for brachial plexus visualization
Study NCT02486549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The Ultrasound will be used for brachial plexus visualization
Study NCT01754454 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Derived MSC
Description: 1×10\^6 UC-MSCs per kg intravenous injection the number of infusions: once a week, for four weeks in a row Time interval: estimate the condition of follow-up visit afer 28 days
Study NCT01127906 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-04531083 100mg
Description: Oral PF-04531083 100mg suspension single dose
Study NCT03454828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: obese carbohydrate diet
Description: The experimental diet will consist of 30% carbohydrates (CHO), 35% protein, and 35% fat. Since the experimental diet is lower in CHO, the fiber and sugar content will be calculated based on total CHO in the same percentage as the control (0.25 g fiber per each kcal of CHO and 18.2% sugar for total CHO).
Study NCT03454828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lean carbohydrate diet
Description: The control diet composition will follow the American Dietary Guidelines of 55% carbohydrates (CHO), 15% protein, and 30% fat. CHO content will be primarily complex CHO of high quality (14 g fiber/1,000 kcals and \<10% of total kcals in the form of sugar).
Study NCT02952131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipoaspiration
Description: Closed Syringe Harvesting Autologous Subdermal Fat
Study NCT02952131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AD-cSVF
Description: Use of Centricyte 1000 to isolate adipose stem/stromal cells via centrifugation
Study NCT02952131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Saline IV
Description: Normal Saline IV containing AD-cSVF
Study NCT04274504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Osteopontin
Description: Serum osteopontin (OPN) was measured by ELIZA and osteopontin gene mutation was analyzed by sequencing and correlated with clinicopathological criteria, response, PFS and OS.
Study NCT01127906 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-04531083 2000mg
Description: Oral PF-04531083 2000mg suspension single dose
Study NCT02368379 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low dose (1 mcg) ACTH stimulation test
Description: Subjects will have baseline cortisol and ACTH drawn followed by administration of 1 mcg/m2 (max 1 mcg) of cortrosyn. Blood will be drawn at 20 and 40 minutes post cortrosyn for peak cortisol assessment of central adrenal insufficiency.
Study NCT02368379 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Overnight metyrapone test
Description: Subjects will receive metyrapone 30 mg/kg (max 3 grams) by mouth at midnight. Blood will be drawn at 0800 AM the following morning for ACTH, cortisol and 11 deoxycortisol for assessment of central adrenal insufficiency.
Study NCT02772874 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05531578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INOVARE® Transcatheter Valve, NexusCath Delivery System, Aureus Expandable Introducer, Balloon Catheter for Pre-Dilation and Compression Device (Crimper)
Description: Transfemoral implantation of the INOVARE® transcatheter valve
Study NCT02375490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Start
Description: Healthy Start was designed to promote physical activity and healthy eating among 3-5 year old children. Specifically, Healthy Start attempts to influence factors at the intrapersonal, interpersonal, organizational, community and physical environment and political levels. These levels of influence are targeted such that from an operational stand point, Healthy Start is composed of six interlinked components: 1) intersectoral partnerships that leads to promoting healthy weights in communities and ECC; 2) The Healthy Start guide for educators; 3) customized training, role modelling and monitoring; 4) an evidence-based resource for both families and educators; 5) supplementary resources from governmental partners; and 6) a knowledge development and exchange, and communication strategy.
Study NCT04178824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discount Intervention
Description: 15% or 30% discount on fruits and vegetables
Study NCT02855229 — intervention group
Intervention type: DRUG
Intervention: Methylphenidate
Description: cross-over, single-dose intervention
Study NCT03535740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib Tablets
Study NCT04984863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetically controlled capsule endoscopy
Description: Magnetically controlled capsule endoscopy (MCE) is a non-invasive detection method independently developed in China that covers the whole digestive tract (except colon) mucosa.
Study NCT01660347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
Study NCT01660347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell transplantation
Description: Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
Study NCT01660347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of therapy complications
Description: Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
Study NCT00655707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Expanded CD34+ Haemopoietic cells
Description: Autologous expanded CD34+ cells obtained by leukapheresis on a single occasion by infusion into the hepatic artery or portal vein.~Patient numbers 01 and 02 will receive 1x109 cells Patient numbers 03 and 04 will receive 1x1010 cells Patient numbers 05 and 06 will receive 2x1010 cells Patient numbers 07 and 08 will receive 5x1010 cells
Study NCT01348308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc (Celsentri)
Description: Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Maraviroc at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks.
Study NCT01348308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Placebo at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks.
Study NCT04413552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INDV-2000
Description: INDV-2000 will be administered as either powder in solution or powder in capsule, depending on dose administered.
Study NCT04413552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as either powder in solution or powder in capsule, depending on dose administered.
Study NCT01876784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vandetanib (SAR390530)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT01876784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib (SAR390530)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT01876784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT00004875 — intervention group
Intervention type: DRUG
Intervention: enoxaparin
Study NCT00004875 — intervention group
Intervention type: DRUG
Intervention: heparin
Study NCT01564888 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ulnar artery compression
Description: Compression of ulnar artery for 2 hours with radial artery hemostasis
Study NCT01564888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ulnar artery compression
Description: Compression of ulnar artery for 2 hours with radial artery hemostasis
Study NCT02267772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: IV Acetaminophen
Study NCT02267772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Morphine
Description: IV Morphine
Study NCT02698202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Breast Tomosynthesis
Description: twice screening examination: standard 2D mammography + Digital Breast Tomosynthesis
Study NCT04695574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Some clinical evaluation performance tests together with procedure of Closed Kinetic Chain Lower Extremity Stability Test
Description: Clinical evaluation methods